Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 4/5/22 → 2/19/24 |
Funding
- IO Biotech ApS: $25,986.00
An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D
- Villano, PhD, John (PI)
- Wang, Peng (Former PI)